Summer Academy

Poster: offer a train the trainer program for Social Media Trainers in Local & Regional governments and businesse

Summer Academy:for social media trainers in local regional governments and business

One of the work packages which Hanzehogeschool emphatically has a role, is Research and Training. In the Summer Academy teachers are trained by translating their knowledge back to their own schools. The Summer Academy is given on 27-30 May 2013, as part of "Opening Up". This project aims to find better service to citizens and businesses through the use of social media and open data. The opening-up project started in October 2011 and lasts three years. Hanze University Groningen is an important partner in the project

Antibiotica in de bodem. Een pilotstudie.

In het kader van een overeenkomst tussen Stichting Kennisontwikkeling Kennisoverdracht Bodem (SKB) en een breed consortium en klankbordgroep is een pilotstudie uitgevoerd naar veterinaire antibiotica in de bodem en het grondwater

TugaTAC Broker: A Fuzzy Logic Adaptive Reasoning Agent for Energy Trading

Smart Grid technologies are changing the way energy is generated, distributed and consumed. With the increasing spread of renewable power sources, new market strategies are needed to guarantee a more sustainable participation and less dependency of bulk generation. In PowerTAC (Power Trading Agent Competition), different software agents compete in a simulated energy market, impersonating broker companies to create and manage attractive tariffs for customers while aiming to profit. In this paper, we present TugaTAC Broker, a PowerTAC agent that uses a fuzzy logic mechanism to compose tariffs based on its customers portfolio. Fuzzy sets allow adaptive configurations for brokers in different scenarios. To validate and compare the performance of TugaTAC, we have run a local version of the PowerTAC competition. The experiments comprise TugaTAC competing against other simple agents and a more realistic configuration, with instances of the winners of previous editions of the competition. Preliminary results show a promising dynamic: our approach was able to manage imbalances and win the competition in the simple case, but need refinements to compete with more sophisticated market. (c) Springer International Publishing Switzerland 2016

NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study.

BACKGROUND: Cell surface NKG2D ligands (NKG2DL) bind to the activating NKG2D receptor present on NK cells and subsets of T cells, thus playing a role in initiating an immune response. We examined tumor expression and prognostic effect of NKG2DL in breast cancer patients. METHODS: Our study population (n = 677) consisted of all breast cancer patients primarily treated with surgery in our center between 1985 and 1994. Formalin-fixed paraffin-embedded tumor tissue was immunohistochemically stained with antibodies directed against MIC-A/MIC-B (MIC-AB), ULBP-1, ULBP-2, ULBP-3, ULBP-4, and ULBP-5. RESULTS: NKG2DL were frequently expressed by tumors (MIC-AB, 50% of the cases; ULBP-1, 90%; ULBP-2, 99%; ULBP-3, 100%; ULBP-4, 26%; ULBP-5, 90%) and often showed co-expression: MIC-AB and ULBP-4 (p = 0.043), ULBP-1 and ULBP-5 (p = 0.006), ULBP-4 and ULBP-5 (p < 0.001). MIC-AB (p = 0.001) and ULBP-2 (p = 0.006) expression resulted in a statistically significant longer relapse free period (RFP). Combined expression of these ligands showed to be an independent prognostic parameter for RFP (p < 0.001, HR 0.41). Combined expression of all ligands showed no associations with clinical outcome. CONCLUSIONS: We demonstrated for the first time that NKG2DL are frequently expressed and often co-expressed in breast cancer. Expression of MIC-AB and ULBP-2 resulted in a statistically significant beneficial outcome concerning RFP with high discriminative power. Combination of all NKG2DL showed no additive or interactive effect of ligands on each other, suggesting that similar and co-operative functioning of all NKG2DL can not be assumed. Our observations suggest that among driving forces in breast cancer outcome are immune activation on one site and tumor immune escape on the other site.RIGHTS : This article is licensed under the BioMed Central licence at http://www.biomedcentral.com/about/license which is similar to the 'Creative Commons Attribution Licence'. In brief you may : copy, distribute, and display the work; make derivative works; or make commercial use of the work - under the following conditions: the original author must be given credit; for any reuse or distribution, it must be made clear to others what the license terms of this work are

The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients

Background:Aspirin use has been shown to lower incidence and mortality in cancer patients. The aim of this population-based study was to determine the effect of postdiagnosis low-dose aspirin use on survival of patients with oesophageal cancer.Methods:Patients with oesophageal cancer (1998-2010) were selected from the Eindhoven Cancer Registry and linked with outpatient pharmacy data regarding aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs). Users were subdivided into both prediagnosis and postdiagnosis or only postdiagnosis users. Parametric survival models with an exponential (Poisson) distribution were used with non-specific death as endpoint.Results:In this study 560 patients were included. Overall, 157 patients (28.0%) were non-users, 293 patients (52.3%) pre-and postdiagnosis (89 aspirin and 204 NSAID users) and 110 patients (19.6%) only postdiagnosis users (16 aspirin and 94 NSAID users). Postdiagnosis aspirin use was associated with overall survival (RR 0.45 (95% CI 0.34-0.60; P<0.001); adjusted rat